Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPLE-2: Osimertinib in treatment-naïve EGFR-mutant NSCLC by TP53 status
2020-001879-33Phase 4Active
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Policlinico Gemelli. Primary endpoints: Progression-free survival (PFS) by TP53 mutational status and Overall survival (OS) by TP53 mutational status. Started Oct 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-001879-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001879-33.